Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anke Cellular Therapeutics
Hefei, Anhui, China
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Anke Cellular Therapeutics is currently conducting Phase 2 clinical trials for its lead candidate AK101 (CD19 CAR-T) for B-cell lymphoma. Preliminary results have shown high complete response rates and manageable safety profiles in patients with relapsed or refractory B-cell malignancies.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Partnerships
Anhui Anke Biotechnology (Group) Co., Ltd.
Beyond the preview
Go deeper on Anke Cellular Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anke Cellular Therapeutics.